Invivyd, Inc. IVVD
Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody ("mAb") therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. PEMGARDA® (pemivibart) is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical activity in the face of viral evolution.
Globally, COVID-19 has caused millions of deaths and lasting health problems in many survivors and remains a significant global health concern, particularly for immunocompromised individuals. COVID-19 persists and continues to impact patients, notably those who are immunocompromised, and combating this disease will require for years to come a variety of prevention and treatment options with demonstrated efficacy and safety. By leveraging our capabilities, which we have developed through our experience with adintrevimab and pemivibart and over five years in the COVID-19 space, we aim to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus ("RSV") and measles.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | — | — | — |
| R&D | $38.3M | $137.3M | $158.7M | $179.2M | $182.9M | — |
| SG&A | $66.9M | $63.4M | $49.1M | $47.0M | $36.5M | — |
| Total operating expenses | $109.0M | $202.3M | $212.8M | $248.0M | $226.9M | — |
| Operating income | -$55.6M | -$176.9M | -$212.8M | -$248.0M | -$226.9M | — |
| Pre-tax income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M | -$38.7M |
| EPS, basic | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 | — |
| EPS, diluted | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 | — |
| Shares, diluted (wtd. avg.) | 172.2M | 118.6M | 109.5M | 108.3M | 42.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $226.7M | $69.3M | $200.6M | $92.1M | $542.2M | $115.0M |
| Receivables | $13.9M | $10.9M | $0 | — | — | — |
| Inventory | — | $25.9M | $0 | — | — | — |
| Total current assets | $247.5M | $100.7M | $224.9M | $376.9M | $616.7M | $117.4M |
| Property, plant and equipment | $1.4M | $1.5M | $1.9M | $2.3M | $83.0K | $0 |
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | $620.1M | $117.4M |
| Accounts payable | $13.7M | $10.4M | $8.0M | $1.5M | $5.8M | $8.2M |
| Total current liabilities | $34.2M | $62.0M | $50.3M | $25.0M | $62.1M | $13.1M |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | $62.1M | $13.1M |
| Retained earnings | -$954.5M | -$902.0M | -$732.1M | -$533.4M | -$292.1M | -$65.3M |
| Total equity | $241.5M | $67.5M | $177.5M | $356.0M | $558.0M | -$65.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$58.1M | -$170.5M | -$173.2M | -$220.0M | -$184.7M | — |
| Depreciation and amortisation | — | — | $480.0K | $41.0K | $1.0K | — |
| Stock-based compensation | $11.6M | $19.8M | $18.7M | $21.6M | $17.8M | — |
| Capital expenditure | $155.0K | $140.0K | $615.0K | $1.7M | $84.0K | — |
| Investing cash flow | -$155.0K | -$140.0K | $280.7M | -$230.7M | -$50.7M | — |
| Financing cash flow | $215.6M | $39.3M | $1.0M | $506.0K | $662.7M | — |
| Buybacks | — | $0 | $1.0K | $4.0K | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-092547.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $25.4M | $53.4M |
| Gross profit | — | — | — | — | — | — |
| Net income | -$38.7M | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |